Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
New Antibiotics
100%
Multidrug-resistant Gram-negative Bacteria
100%
Multidrug-resistant Organisms
75%
High Risk
25%
Patient Demographics
25%
Empirical Therapy
25%
Novel Antibiotics
25%
Gram-negative Infections
25%
Imipenem
25%
Cefiderocol
25%
Meropenem-vaborbactam
25%
Ceftazidime-avibactam
25%
Ceftolozane/tazobactam
25%
New Mode of Action
25%
Nursing and Health Professions
Gram Negative Infection
100%
Infection
66%
Patient Population
33%
Morbidity
33%
Meropenem
33%
Cefiderocol
33%
Vaborbactam
33%
Ceftolozane
33%
Avibactam Plus Ceftazidime
33%
Imipenem
33%
Tazobactam
33%
Medicine and Dentistry
Gram-Negative Bacterial Infection
100%
Antibiotics
100%
Infection
40%
Patient Population
20%
Meropenem
20%
Morbidity
20%
Imipenem
20%
Cefiderocol
20%
Tazobactam
20%
Ceftolozane
20%
Vaborbactam
20%
Avibactam Plus Ceftazidime
20%
Empirical evidence
20%
Pharmacology, Toxicology and Pharmaceutical Science
Antibiotics
100%
Gram Negative Infection
100%
Infection
40%
Morbidity
20%
Imipenem
20%
Meropenem
20%
Cefiderocol
20%
Tazobactam
20%
Ceftolozane
20%
Avibactam Plus Ceftazidime
20%
Vaborbactam
20%